2012 Early Detection Seminar Series
Seminar & Discussion: 5:30pm - 6:30pm
Reception: 6:30pm - 7:00pm
The Early Detection Seminar Series presents seminars highlighting new research in Early Cancer Detection. This seminar series alternates months with the Information Sciences in Imaging Seminars.
Seminars will be held in Lucile Packard Children's Hospital (LPCH) Freidenrich Auditorium or Li Ka Shing Learning Center (LKSC), Room LK130, Munzer Auditorium, Clark Auditorium, or Clark S360.
NOTE: This seminar does not run through the Summer months.
Jan 26, 2012
Proteomic Strategies for Breast Cancer Early Detection
Sharon Pitteri, PhD, Assistant Professor, Radiology
Stanford University School of Medicine
Mar 22, 2012
Prostate Active Surveillance Study (PASS): Rationale, design and implementation of a multi-institutional active surveillance cohort and biorepository
Daniel W Lin, MD, Associate Professor
Chief of Urologic Oncology, University of Washington
Apr 26, 2012
Integrated Proteomic Strategies for Discovering Novel Biomarkers: An Example with Pancreatic Cancer.
Vathany Kulasingam, PhD, Assistant Professor
Department of Clinical Biochemistry, University of Toronto
Oct 25, 2012
Nanocytology: Transforming Cancer Screening
Vadim Backman, PhD, Professor
Biomedical Engineering, Northwestern University
Although compelling evidence suggests that cellular nanoscale architecture and nanoscale environment where molecular interactions take place can significantly affect macromolecular processes, biological ramifications of cellular nanoscale organization have been largely unexplored. By use of a novel optical microscopy technique termed nanocytology, which allows for quantification of the statistical properties of intracellular structure at the nanoscale, we have demonstrated that alterations in the nuclear nanoarchitecture are some of the earliest events in carcinogenesis and a marker of field carcinogenesis that precedes any known morphological changes in cellular microarchitecture. This appears to be a universal event in carcinogenesis, which is supported by our data in six types of cancer: colon, pancreatic, esophageal, lung, ovarian and thyroid cancers. A significant application of nanocytology is in cancer screening enabled by the detection of field carcinogenesis via the analysis of the nanoarchitecture of cells obtained from easily accessible tissue sites. Our data from multi-institutional clinical trials demonstrate that nanocytology has the potential to become a new platform for cancer screening broadly applicable to a number of organ sites from which cellular specimen can be obtained by brushing. The talk will discuss the potential applications of nanocytology as a prescreen for colonoscopy and a guide to surveillance.